We investigated the effects of ursodeoxycholic acid (UDCA, 60 µg/day/100 g b.wt.) on the impairment induced by maternal obstructive cholestasis during pregnancy (OCP) in the rat placenta-maternal liver tandem excretory pathway. A blunted catheter was implanted in the common bile duct on day 14 of pregnancy and the tip was cut on day 21. 
INTRODUCTION
Carrier proteins located in the basolateral and apical plasma membranes of hepatocytes are responsible for bile acids (BAs) uptake and secretion into bile (Meier and Stieger, 2002) .
During intrauterine life, when the liver is not yet mature, efficient transfer of fetal BAs across the placenta, together with normal maternal hepatobiliary function maintain fetal BA levels within the physiological range. Previous studies have shown that carriers located in the trophoblast plasma membranes play a role in the vectorial fetal-to-maternal translocation of cholephilic compounds, such as BAs (Marin et al., 1990; Marin et al., 1995) and bilirubin (Serrano et al., 2002) . Maternal hypercholanemia may challenge transplacental elimination of fetal BAs through the creation of inversely directed gradients as compared to the physiological situation (Monte et al., 1995) , and by impairing the placental ability to carry out vectorial BA transfer (Macias et al., 2000) . Moreover, obstructive cholestasis during pregnancy (OCP) in rats results in an accumulation of BAs in fetuses, a situation that is also transiently observed later in juvenile animals born from cholestatic mothers (Monte et al., 1996) . Exposure of the fetal liver to high BA levels is probably involved in the delayed maturation of hepatobiliary function observed in these young rats (Monte et al., 1996; El-Mir et al., 1997) .
In humans, intrahepatic cholestasis of pregnancy (ICP) is accompanied, among other maternal and fetal alterations (Reid et al., 1976; Mullally and Hansen, 2002) , by a reduced ability to transport BAs across the trophoblast plasma membrane (Serrano et al., 1998) . Treatment with ursodeoxycholic acid (UDCA), which has beneficial effects in several cholestatic liver diseases (Poupon and Poupon, 1995; Lazaridis et al., 2001; Kowdley, 2000) , is able to mitigate pruritus and enzyme elevations in the serum of women with ICP (Palma et al., 1992; Floreani et al., 1994; Brites et al., 1998) . Because UDCA was also found to have a positive effect on ICP placentas, at least as far as BA transport by trophoblast plasma membrane vesicles was concerned (Serrano et al., 1998) , in the present study we intended to further characterize structural and functional aspects of the beneficial effects of UDCA on maternal hypercholanemia-induced impairment of the rat placenta-maternal liver tandem excretory pathway for fetal BAs. 
MATERIALS AND METHODS

Experimental goups
Non-fasting pregnant Wistar CF rats (Animal House, University of Salamanca, Spain) were used. The experiments were approved by the Local Ethical Committee. On day 14 of pregnancy all animals were anesthetized with sodium pentobarbital (50 mg/kg body weight, i.p., Abbot, Madrid, Spain) to either sham-operate them (Control) or produce a complete obstructive cholestasis (OCP) by implantation of a blunted catheter in the common bile duct (Monte et al., 1996) . During the following week part of these animals received daily intragastric administration of 60 µg UDCA in 60 µL of 75 mM NaCl, 50 mM Na 2 CO 3 , pH 8.3, per 100 g b.wt. (OCP+UDCA group, n=60) . The rest of the cholestatic rats (OCP group, n=70) received only the vehicle.
"In vivo" experiments
On day 21 the animals were anesthetized again. Cannulation of the common bile duct was performed in Controls. In OCP and OCP+UDCA groups the blunted tips of the catheters implanted were cut, thereby allowing free bile flow. This was measured gravimetrically. BA concentrations were determined enzymatically (Talalay, 1960) . The doses of [ 14 C]-glycocholate ([ 14 C]-GC; specific radioactivity 46.7 mCi/mmol) used in different types of experiments were selected based on previous studies and were administered once BA output had reached an approximate steady-state after bile drainage (Macias et al., 2000) . To evaluate BA uptake and secretion by the maternal liver 5 nmol [ 14 C]-GC in 150 mM NaCl, 5 mM glucose was administered through the maternal jugular vein as a 5 min bolus (50 µL/min).
Transfer of [ 14 C]-GC across the placenta-maternal liver tandem was measured using "in situ"
single-pass perfused placenta. 250 nmol [ 14 C]-GC was administered with the perfusate -137 mM NaCl, 2.7 mM KCl, 1.05 mM MgCl 2 , 1.80 mM CaCl 2 , 12 mM NaHCO 3 , 0.4 mM NaH 2 PO 4 , 5 mM glucose, 0.05% (w/v) heparin, 10 mM Hepes, pH 7.40 at 37°C -through the umbilical artery over 5 min (500 µL/min) and radioactivity in maternal serum and bile was determined (Macias et al., 2000 , Briz et al., 1998 . Placental [ 14 C]-GC content was measured in similar experiments, except that 2 or 10 min after finishing [ 14 C]-GC administration the perfused placenta and the remaining non-perfused placentas and their fetuses were collected to measure radioactivity. The amount of tissue able to carry out placental exchange was determined by measuring the magnitude of the diffusional pathway for antipyrine.
Fetal/maternal serum antipyrine concentration ratios were assayed as previously described following administration through the maternal jugular vein (100 mg bolus plus 0.5 mg/min infusion) (Macias et al., 2000) .
Experiments on plasma membrane vesicles
Maternal-facing trophoblast plasma membrane (mTPM) vesicles were isolated from rat placenta as previously described (Macias et al., 2000 , Bravo et al., 1998 
Determination of gene expression
RNA from snap-frozen placentas and livers was isolated using RNeasy spin columns from Qiagen (Izasa, Barcelona, Spain) and measured with the RiboGreen RNA-Quantitation kit (Molecular Probes, Leiden, The Netherlands). Reverse transcription was carried out with 1 µg of total RNA, using random nanomers and Enhanced Avian RT-PCR kit (Sigma-Genosys, Cambridge, UK).
The presence of the selected mRNAs was investigated by the detection and subsequent sequencing of mid-size fragments (Table 1) were used in all determinations as external calibrators and the levels of 18S rRNA in each sample was used to normalize the results.
Because major changes affected mRNA levels of a typical basolateral carrier (i.e., Oatp2) and a typical apical exporter (i.e., Mrp2), for which antibodies were available, they were selected to carry out western blot analysis on crude placental cell membrane preparations. As positive controls we used rat liver basolateral (bLPM) and canalicular (cLPM) plasma membranes (Bossard et al., 1993) . Membrane preparations (15 µg protein of either bLPM or cLPM, or 50 µg protein of placental cell membranes) were diluted in sample buffer under reducing conditions, incubated for 3 min at 100°C, subjected to 7.5% or 15% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Polyclonal antibodies against rat Oatp2 (K15, dilution 1:7500) and Mrp2 (K13, dilution 1:3000) were used as primary antibodies.
Histological examination and data analysis
Light and transmission electron microscopical examinations of placental tissue were carried out as previously reported (Macias et al., 2000) . Morphometric analysis was performed using NIH Image V1.62 software (National Institutes of Health, USA).
Results are means ± SEM. Significance of differences of OCP and OCP+UDCA versus Control was determined by the Bonferroni method of multiple range testing. Kinetic parameters were calculated after fitting the data from transport studies with an iterative nonlinear least-squares method, using the UltraFit-v2.1 software (Biosoft, Cambridge, UK) to the Michaelis-Menten equation for a single carrier system. To characterize pharmacokinetic parameters a model-independent method based on the theory of statistical moments was used (Yamaoka et al., 1978) .
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RESULTS
Morphological, biochemical, histological and molecular changes
Morphological and biochemical changes are in agreement with previous studies using OCP rats (El-Mir et al., 1997; Macias et al., 2000; Monte et al., 1996) . Some of them were prevented by UDCA ( Table 2) . Atrophy of trophoblastic tissue in OCP placentas with dilated maternal vascular lacunae -to approximately 189% of Control -was seen. These alterations were in part corrected in OCP+UDCA placentas in which morphometric analysis revealed that fetal tissue was restored to 92% of Control value (Figure 1 ). At subcellular level ( Figure   2 ) syncytiotrophoblastic cells from the OCP group displayed hydroponic degeneration. Cells appeared with a very dilated pericanalicular space, a highly vacuolar cytoplasm, and a lack of microvilli on mTPM. These alterations were partly prevented by UDCA. The proportion of trophoblast in the placentas, as determined by placental lactogen type II (rPLII) -a specific trophoblastic marker during the last stages of rat gestation (Faria et al., 1990; Shah et al., 1998 ) -was reduced by OCP, but restored by UDCA ( Figure 3B ).
When mRNA level was related to that of rPLII, increases in relative abundance of mRNA for all studied carriers in OCP and OCP+UDCA were observed ( Figure 3C ). When total placental level was calculated, no change or a tendency towards increased expression of BA and organic anion carriers in whole OCP placentas, that was statistically significant only for Oatp1 and Oatp2, was found. However in OCP+UDCA placentas the mRNA levels for all of them were enhanced ( Figure 3B ). The highest levels were for Oatp2 and Mrp2. Western blot analysis of these two representative carriers, indicated that they were not detectable by this technique in Control ( Figure 3B ). However, consistently with changes in mRNA levels, they were seen in OCP and OCP+UDCA placentas as clear bands, but not intense enough to permit accurate quantitative analysis ( Figure 3A ).
"In vitro" functional studies
Kinetic parameters for ATP-dependent [ 14 C]-GC uptake by mTPM versus substrate concentrations ( Figure 4A ) indicated that, in agreement with previous studies (Macias et al., 2000) , the transport efficiency, as defined by the Vmax-to-KM ratio, was reduced in mTPM from OCP placentas. This was mainly caused by an increase of the KM. UDCA treatment did not significantly modify Vmax but restored the KM-value to normal and hence reversed the efficiency of this transport to values close to those of Control placentas ( Figure 4B ). 
"In vivo" functional studies
Once bile flow is allowed on day 21, this and BA output were initially higher in OCP and OCP+UDCA than in Control ( Figure 5 ). This was followed by a progressive decrease in BA output below Control levels, probably due to the fact that, in the absence of a normal enterohepatic circulation, most of the BA pool is located in the liver. By contrast, after an initial decrease, bile flow was maintained in both OCP and OCP+UDCA at a similar level to that found in Control. Cholangiocyte proliferation and changes in its secretory function associated to rat biliary obstruction for 1 week (Alpini et al., 2002) Table 3 it can be calculated that, in agreement with previous studies (Macias et al., 2000) , the fraction of the [ 14 C]-GC dose administered through the umbilical artery that was secreted into bile over 2 h after administration was 2.15% in Controls. This was greatly reduced to 0.54% by OCP and partly restored to 1.15% in OCP+UDCA group. No detectable radioactivity was found in unperfused placentas or their fetuses collected at 2 or 10 min, (data not shown). When tissue collection from perfused placentas was carried out 2 min after the end of [ 14 C]-GC administration, the dose fraction of [ 14 C]-GC taken up into placentas (administered dose = 100%) calculated from results shown in Table 3 was Control (2.22%) > OCP+UDCA (1.21%) > OCP (1.01%).
A both the Control and OCP+UDCA groups, but not in the OCP animals, in which the amount secreted into bile was significantly lower than that taken up by the placenta (Table 3) .
Measurements of radioactivity in placentas at min 10 as compared with that found at min 2 indicated that the proportion of [ 14 C]-GC remaining in this organ after that time was smaller in Controls than in the other two groups (Table 3) .
When [ 14 C]-GC was injected through the maternal jugular vein (Figure 8) 
DISCUSSION
In agreement with previous findings by our group and others (Macias et al., 2000 , Klaassen, 1974 , diminished and slower secretion of exogenously administered bile acids to rats after releasing obstructive cholestasis was observed. This is consistent with the known reduction occurring after BDL in the expression of rat sinusoidal BA carriers, while canalicular exporter pumps, Mrp2 and Bsep are decreased or partially maintained, respectively (Trauner et al., 1999) .
Although improvement of the drug-induced cholestasis in the rat by UDCA has been reported (Jacquemin et al., 1993) , its beneficial effect after BDL is limited (Poo et al., 1992; Purucker et al., 2001; Hinz et al., 1997) . In the present study, UDCA administration to OCP rats also resulted in only a partial beneficial effect on liver ability to secrete [ 14 C]-GC. Nevertheless, this probably contributed to enhance the elimination of [ 14 C]-GC when this was administered through the umbilical artery.
One of the most striking findings of the present study was the effect of UDCA on trophoblast.
Morphological, molecular and functional measurements indicated a dramatic reduction in the amount of functional trophoblast in OCP placentas. As has been reported by others in several tissues (Abdel-Aziz et al., 1991) , inflammatory processes associated with BA accumulation probably account for fibrogenesis, accumulation of extracellular matrix and necrosis also present in OCP placentas (data not shown), all of which may contribute to reducing transplacental exchange. UDCA prevented the OCP-induced loss of trophoblast, structural alterations were limited and the functional test based on antipyrine diffusion was partly restored.
Another important contribution is the confirmation of preliminary observations (St-Pierre et al., 1999) regarding the presence of Oatp1, Oatp2 and Oatp4 in rat placenta. Assuming that these carriers are located only in the trophoblast, it could be calculated that the relative abundance of their mRNA as compared to rPL II was enhanced in OCP and OCP+UDCA.
However, because the amount of trophoblast was reduced by OCP, the total levels in whole placentas of this group were not markedly higher than in Control. By contrast, because of UDCA restored the amount of trophoblast, total placental mRNA levels for these carriers were enhanced in a moderate-to-marked range in OCP+UDCA. This could in part account for This article has not been copyedited and formatted. The final version may differ from this version. While placental [ 14 C]-GC uptake occurred over 5 min, its output toward the mother and then into bile took much longer, especially in the OCP animals, supporting the concept that an export mechanism located in the apical membrane of the trophoblast is probably the limiting step in the overall process of BA elimination by the placenta-maternal liver tandem (Briz et al., 1998) . Increases in the levels of mRNA for uptake and export carriers were probably accompanied by enhancements in the amount of these proteins in trophoblastic cells, as indicated by western blot analysis of two representative carriers, Oatp2 and Mrp2. However, the lack of normal micrivilli in trophoblast plasma membranes in OCP placentas together with the fact that, even when purified apical membranes were used, the efficiency of ATP-dependent [ 14 C]-GC transport was reduced in this group, suggests that carrier overexpression was not enough to counterbalance other negative changes in the plasma membrane composition/structure or in the maturation/sorting process affecting the function of the carriers and that such negative effects would be responsible for the reduction in carrier ability to export BAs.
Moreover, the possibility that part of the discrepancy between enhanced expression levels and reduced transport ability could be attributed to the fact that some of these transporters may be present in intracellular compartments, which are not actively involved in BA transport across the trophoblast, should be considered. Treatment with UDCA did not reduce the relative 
